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Case report
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Abstract
Herein we report a case of a cystic fibrosis child who was simultaneously infected with Burkholderia cepacia genomovar III
and Burkholderia vietnamiensis. After antimicrobial therapy only B. cepacia genomovar III persisted.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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A 23 months-old white cystic fibrosis boy was
addressed to a clinical laboratory in Recife, Brazil, due
to his first noticed episode of acute bronchitis. The
patient lives in Maceio, a city situated 248 km from´
Recife. Cystic fibrosis was suspected in the first trimes-
ter of life due to a positive immunoreactive trypsine test
and confirmed by sweat pilocarpine iontophoresis w1x.
Additionally, homozygotic Delta F 508 mutation was
detected at that time. He started pancreatic enzymes at
6 months of age because of malnutrition and fatty stools.
At 6 months of age he was severely malnourished. Z-
scores with reference standards from National Center
for Health Statistics w2x were: height for agey3.61,
weight for agey2.72 and weight for height 0.12. At 33
months he was recovering: height for agey1.01, weight
for agey0.92, and weight for height 0.29. His respira-
tory condition at this time was good. Cough was mild
and intermittent and Shwachman score w3x was 80.
Bacteriological examination of respiratory samples in
the present cystic fibrosis unit was set up in December
2000. Thus far (July 2002) 134 cultures have been
performed on specimens obtained from the 40 patients
attending this center. Twenty-two patients provided, at
least once, a Pseudomonas aeruginosa positive speci-
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men; 16 patients had a mucoid P. aeruginosa morpho-
type. Two patients were infected with Burkholderia
cepacia complex alone, and eight were infected with B.
cepacia complex and P. aeruginosa. As a policy to
avoid costs, cultures are not routinely done after che-
motherapy unless the clinical picture does not improve.
Antibody levels to common cystic fibrosis pathogens
are not being determined.
As sputum specimens of the present patient could not
be obtained, throat swabs were taken for culturing. On
Sheep blood agar and McConkey medium approximately
100 colonies of a mucoid strain of P. aeruginosa were
recognised. On B. cepacia selective agar w4x 20 colonies
showing two different morphological types were distin-
guished. One of them, was phenotypically w5x identified
as B. cepacia genomovar I or III; the other as Burkhold-
eria vietnamiensis. Further tests involving whole-cell
protein electrophoresis w6x and amplification of the recA
gene followed by restriction fragment length polymor-
phism (RFLP) analysis w7x permitted a definitive clas-
sification of the isolates as B. cepacia genomovar III
(recA RFLP type G) and B. vietnamiensis (recA RFLP
type A). Haemophilus influenzae and Staphylococcus
aureus were not detected despite the use of chocolate
agar and blood agar under anaerobic incubation.
The patient was treated with oral ciprofloxacin 125
mg twice daily, oral sulfamethoxazoleytrimethoprim 240
mg twice daily, and aerosolised amikacin 250 mg twice
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daily, for 14 days. B. vietnamiensis was susceptible to
the three drugs, while B. cepacia genomovar III was
resistant to amikacin, but susceptible to ciprofloxacin
and to sulfamethoxazoleytrimethoprim. P. aeruginosa
was only resistant to sulfamethoxazoleytrimethoprim.
Antibiograms were carried out by using the disk diffu-
sion method w8x. The patient remained clinically well
for 6 months when he returned due to a new episode of
acute bronchitis; throat swabs were again taken. The
new cultures were positive for the P. aeruginosa mucoid
variant and B. cepacia genomovar III, but not for B.
vietnamiensis. The latter and the initial P. aeruginosa
and B. cepacia genomovar III isolates showed the same
biochemical reactivity pattern and drug-resistance pro-
files, and thus did not become resistant to the drugs
used in the therapy.
Cystic fibrosis patients have long been recognised as
prone to be colonised with ‘B. cepacia’, an organism
sometimes associated with fatal bacteraemia, the so
called ‘cepacia syndrome’ w9x. The recognition that ‘B.
cepacia’ is not a single organism, but a complex
comprising at least nine different bacterial species or
genomovars w10x, arose interest on whether these species
are equally virulent and which of them are more preva-
lent among cystic fibrosis patients. Recent reports point
out B. cepacia genomovars II (B. multivorans) and III
as the principal pathogens of the complex w11,12x.
Putative virulence factors, such as the cable pilus w13x
and a genetic segment, esmR w14x have been reported
in some B. cepacia genomovar III strains and seemed
to be associated with enhanced capacity for colonisation
and spreading in cystic fibrosis community. However,
since many isolates belonging to genomovar III lack
such factors, their actual role in virulence or transmis-
sibility is questioned w11x. B. vietnamiensis, a bacterium
used as promoter of growth in rice crops w15x, appears
to infect only a small number of North American cystic
fibrosis patients and little is known about its clinical
significance in cystic fibrosis patients w11,16x. Remark-
ably, an outbreak of subclinical mastitis was reported in
dairy sheep in Spain and was also caused by B. cepacia
genomovar III and B. vietnamiensis w17x. Such a ‘dou-
ble’ outbreak was also reported by Van Laer et al. w18x
who described an outbreak of two types of ‘B. cepacia’
with septicaemia on a cardiology ward. Retrospective
analysis of these two types by means of recA RFLP
analysis identified both as B. stabilis (PV, unpublished
data). It seems likely that B. cepacia complex bacteria
like B. cepacia genomovar III, B. vietnamiensis, and B.
stabilis share common environments and, therefore, they
might simultaneously be colonising niches in susceptible
hosts such as the respiratory tract of cystic fibrosis
patients. The presence of multiple genomovars in one
specimen may identify a prolonged mixed infection, or,
alternatively, a brief period of strain replacement
w12,19,20x. In order to evaluate the relation between
genomovar status, virulence, and clinical outcome of
infection, it will be required to recognise these multiple
infections. As the colonial morphology of all B. cepacia
bacteria (both within and between individual clones) is
rather variable, the detection of mixed infections requires
the examination of multiple different colonies.
Acknowledgments
PV is indebted to the Fund for Scientific Research—
Flanders for financial support.
References
w1x Gibson LE, Cooke RE. A test for concentration of electrolytes
in sweat in cystic fibrosis of the pancreas utilizing pilocarpine
iontophoresis. Pediatrics 1959;23:545–9.
w2x National Center for Health Statistics. Available from:
www.cdc.govygrowthchartsy
w3x Shwachman H, Kulczycki LL. Long term study of one hundred
and five patients with cystic fibrosis. Am. J. Dis. Child
1958;96:6–26.
w4x Henry D, Campbell M, McGimpsey C, et al. Comparison of
isolation media for recovery of Burkholderia cepacia complex
from respiratory secretions of patients with cystic fibrosis. J.
Clin. Microbiol. 1999;37:1004–7.
w5x Henry DA, Mahenthiralingam E, Vandamme P, Coenye T,
Speert DP. Phenotypic methods for determining genomovar
status of the Burkholderia cepacia complex. J. Clin. Microbiol.
2001;39:1073–8.
w6x Vandamme P, Holmes B, Vancanneyt M, et al. Occurrence of
multiple genomovars of Burkholderia cepacia in cystic fibrosis
patients and proposal of Burkholderia multivorans sp. nov. Int.
J. Syst. Bacteriol. 1997;47:1188–200.
w7x Mahenthiralingam E, Bischof J, Byrne SK, et al. DNA-based
diagnostic approaches for identification of Burkholderia cepa-
cia complex, Burkholderia vietnamiensis, Burkholderia multi-
vorans, Burkholderia stabilis, Burkholderia cepacia
genomovars I and III. J. Clin. Microbiol. 2000;38:3165–73.
w8x Jorgensen JH, Turnidge JD, Washington JA. Antibacterial
susceptibility tests: dilution and disk diffusion methods. In:
Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH,
editors. 7th ed.. Manual of clinical microbiology. Washington,
DC: American Society for Microbiology, ASM Press, 1999. p.
1526–46.
w9x Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia
infection in cystic fibrosis: an emerging problem. J. Pediatr.
1984;104:206–10.
w10x Coenye T, Vandamme P, Govan JRW, LiPuma JJ. Taxonomy
and identification of the Burkholderia cepacia complex. J.
Clin. Microbiol. 2001;39:3427–36.
w11x LiPuma JJ, Spilker T, Gill LH, Campbell PW, Liu L, Mahen-
thiralingam E. Disproportionate distribution of Burkholderia
cepacia complex species and transmissible markers in cystic
fibrosis. Am. J. Respir. Crit. Care Med. 2001;164:92–6.
w12x Mahenthiralingam E, Vandamme P, Campbell ME, et al.
Infection with Burkholderia cepacia complex genomovars in
patients with cystic fibrosis: virulent transmissible strains of
genomovar III can replace B. multivorans. Clin. Infect. Dis.
2001;33:1469–75.
w13x Sun L, Jiang R, Steinbach S, et al. The emergence of a highly
transmissible lineage of cblq Pseudomonas (Burkholderia)
294 M. Magalhaes et al. / Journal of Cystic Fibrosis 1 (2002) 292–294˜
cepacia causing CF center epidemics in North America and
Britain. Nat. Med. 1995;1:661–6.
w14x Mahenthiralingam E, Simpson D, Speert DP. Identification and
characterization of a novel DNA marker associated with cystic
fibrosis. J. Clin. Microbiol. 1997;35:808–16.
w15x Tran Van V, Mavingui P, Berge O, Balandreau J, Heulin T.
Promotion de croissance du riz inocule par une bacterie´ ´
fixatrice d’azote, Burkholderia vietnamiensis, isolee d’un sol´
sulfate du Viet-nam. Agronomie 1994;14:697–707.´ ˆ
w16x Speert DP, Henry D, Vandamme P, Corey M, Mahenthiralingam
E. Epidemiology of Burkholderia cepacia complex in patients
with cystic fibrosis, Canada. Emerg. Infect. Dis. 2002;8:181–
7.
w17x Berriatua E, Ziluaga I, Miguel-Virto C, et al. Outbreak of
subclinical mastitis in a flock of dairy sheep associated with
Burkholderia cepacia complex infection. J. Clin. Microbiol.
2001;39:990–4.
w18x Van Laer F, Raes D, Vandamme P, et al. An outbreak of
Burkholderia cepacia with septicaemia on a cardiology ward.
Infect. Control Hosp. Epidemiol. 1998;19:112–3.
w19x Chen JS, Whitzmann KA, Spilker T, Fink RJ, LiPuma JJ.
Endemicity and inter-city spread of Burkholderia cepacia
genomovar III in cystic fibrosis. J. Pediatr. 2001;139:643–9.
w20x Ledson MJ, Gallager MJ, Corkill JE, Hart CA, Walshaw MJ.
Cross infection between cystic fibrosis patients colonised with
Burkholderia cepacia. Thorax 1998;53:432–6.
